Abstract:BackgroundSince China has a unique system of delivering HIV care that includes all patients' records. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART are understudied in the China despite subsequent virological suppression (viral load < 50 copies/mL) is unknown.MethodsThe authors conducted a retrospective cohort study using data from the national HIV treatment sub-database of Zhejiang province to identify records of HIV+ patients. Patient records were included if they were < 16 years of age, had an initial CD4 count < 100 cells/mu L, were on continuous HAART for at least one year by the end of December 31, 2014; and achieved and maintained continued maximum virological suppression (MVS) (< 50 copies/ml) by 9 months after starting HAART. The primary endpoint for analysis was time to first CD4+ T cell count recovery (>= 200, 350, 500 cells/mu L). Cox proportional hazard regression was used to identify the risk factors for CD4+ T cell count recovery to key thresholds (200350, 350-500, >= 00 cells/mu L) by the time of last clinical follow-up (whichever occurred first), key thresholds (follow-up date for analysis), with patients still unable to reach the end-points being censored by the end December 31, 2014 (follow-up date for analysis).ResultsOf the 918 patients who were included in the study, and the median CD4+ T cell count was 39 cells/mu L at the baseline. At the end of follow-up, 727 (79.2%), 363 (39.5%) and 149 (16.2%) patients had return to >= 200, 350, and 500 cells/mu L, respectively. Kaplan-Meier analysis demonstrated that the rate of patients with CD4+ count recovery to >= 200, 350, and 500 cells/mu L after 1 year on HAART was 43.6, 8.6, and 2.5%, respectively, after 3 years on treatment was 90.8, 46.3, and 17.9%, respectively, and after 5 years on HAART was 97.1, 72.2, and 36.4%, respectively. The median time to return to 200-350, 350-500, >= 500cells/mu L was 1.11, 3.33 and 6.91 years, respectively. Factors of age (aHR = 0.77, 95% CI 0.61-0.97), baseline CD4+ count (aHR = 1.60, 95% CI 1.37-1.86), initial regimens, changes in regimen (aHR = 0.58, 95% CI 0.49-0.69), and inclusion of a cotrimoxazole prophylaxis (aHR = 0.66, 95% CI 0.51-0.85) were associated with CD4+ T cell count recovery.ConclusionThe proportion of patients with initially low CD4 counts after nine months of treatment and that achieved continuous virological suppression was greater than 70% for persons with CD4+ count >= 350. Conversely, only 35% of patients recovered to levels of 500 cells/mu L after 5 years of treatment, and levels continued to rise significantly with further long-term HAART. Early HAART intervention will be necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

Reduced Thymic Output is a Major Mechanism of Immune Reconstitution Failure in HIV-infected Patients after Long-Term Antiretroviral Therapy.

Thymic Exhaustion and Increased Immune Activation Are the Main Mechanisms Involved in Impaired Immunological Recovery of HIV-Positive Patients under ART

Immune reconstitution in HIV-1 infected individuals with long-term highly active antiretroviral therapy

Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological non‐responders

Pathogenesis of impaired immune reconstitution in human immunodeficiency virus-infected patients

Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression

HIV-Induced Thymic Insufficiency and Aging-Related Immunosenescence on Immune Reconstitution in ART-Treated Patients

Immunological recovery failure in cART-treated HIV-positive patients is associated with reduced thymic output and RTE CD4+ T cell death by pyroptosis

Determinants of CD4+ T Cell Recovery During Suppressive Antiretroviral Therapy: Association of Immune Activation, T Cell Maturation Markers, and Cellular HIV-1 DNA.

Advances in Mechanism of HIV-1 Immune Reconstitution Failure: Understanding Lymphocyte Subpopulations and Interventions for Immunological Nonresponders

Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy

Recent advances in poor HIV immune reconstitution: what will the future look like?

Cellular and molecular insights into incomplete immune recovery in HIV/AIDS patients

The Factors Related To Cd4+T-Cell Recovery And Viral Suppression In Patients Who Have Low Cd4+T Cell Counts At The Initiation Of Haart: A Retrospective Study Of The National Hiv Treatment Sub-Database Of Zhejiang Province, China, 2014

Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection

Failure of CD4+ T-cell Recovery upon Virally-Effective cART: an Enduring Gap in the Understanding of HIV+ Immunological non-Responders

Single-cell sequencing resolves the landscape of immune cells and regulatory mechanisms in HIV-infected immune non-responders

The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy

Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery

Increased early activation of CD56dimCD16dim/- natural killer cells in immunological non-responders correlates with CD4+ T-cell recovery

Analysis of B cell phenotype and the restoration of antiretroviral therapy in chronic human immunodeficiency virus type 1 infection